| Document Date: 2013-03-14 11:56:19
Open Document File Size: 150,82 KBShare Result on Facebook
City Geneva / Amsterdam / Moxifloxacin / / Company Waksman SA. / Elsevier Publishing Company / / Country Switzerland / United States / Italy / Iran / South Africa / India / / Facility National Library of Medicine / / IndustryTerm tuberculosis laboratory technology / laboratory systems / widespread international media attention / / MedicalCondition DF / totally drug-resistant tuberculosis strains / Wang X. Global tuberculosis / TB / either tuberculosis / JE / HIV / resistant tuberculosis / multidrugresistant tuberculosis / disease / strain / drug-sensitive tuberculosis / Mycobacterium tuberculosis / totally drug-resistant tuberculosis / increasingly resistant tuberculosis / resistant pulmonary tuberculosis / MS / drugresistant tuberculosis / extensively drug-resistant tuberculosis / drug-resistant tuberculosis / multidrug-resistant tuberculosis / tuberculosis / briefly present new tuberculosis / / NaturalFeature Gler MT / / Organization World Health Organization / WHO Stop TB Department / / Person Ben Amor Due / Timothy Sullivan / / Position usher / / Product kanamycin / pyrazinamide / Linezolid / isoniazid / / PublishedMedium PLoS One / / Technology drug discovery / tuberculosis laboratory technology / drug development / / URL http /
SocialTag |
Whatʼs in a name? The future of drug-resistant tuberculosis classification Timothy Sullivan, Yanis Ben Amor Due to a recent resurgence in tuberculosis research focused on drug development, several new antituberculosis d